Novo Nordisk A/S has escalated its legal efforts against Hims & Hers Health to ban the sale of compounded versions of its weight-loss drug Wegovy, aiming to combat increasing competition from look-alike products. This legal battle comes as Novo prepares to launch Wegovy in vials and anticipates gaining access to 15 million new patients with expected Medicare coverage in 2026. However, concerns about pricing pressures and a forecasted decline in sales amidst fierce competition, particularly from Eli Lilly, pose significant hurdles for the company's growth.
“Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co.”
“Novo Nordisk $NVO is suing to permanently ban Hims & Hers Health from selling compounded versions of their weight loss drugs.”
“Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill.”
“$NVO is suing $HIMS over copycat weight loss drugs. @ScottGottliebMD breaks down what it means for the industry.”
“With Medicare coverage of obesity drugs slated to begin in mid-to-late 2026, Novo Nordisk (NVO) CEO Mike Doustdar believes the company can add 15M new patients for its weight loss drugs. Considering 'specifically our products and the target group, I think around 15 million people would be a good number to target,' he told CNBC.”
“The exec added that Novo is currently in negotiations with the federal government to determine when coverage would begin.”
“Novo Nordisk would be considered one of those high-growth-potential healthcare stocks. But what makes it even more attractive right now is its low valuation. The stock is cheap right now, trading at 13 times earnings, so it looks like a no-brainer.”
“Experts predict that the GLP-1 market will grow to $254 billion by 2034, which would be a compound annual growth rate of 17%, so this market is not slowing down, and Novo Nordisk stands to reap the benefits for years.”
“For 2026, sales growth is targeted at 5% to 13% and will be positively impacted by a reversal of sales rebate provisions in the U.S.”
“Novo Nordisk (NYSE:NVO) is pursuing legal and regulatory action against Hims & Hers and other companies selling compounded versions of its obesity drugs. The US Food and Drug Administration has backed enforcement against non FDA approved compounded obesity drug copies.”
“management is already guiding for a 5% to 13% sales and earnings decline in 2026 due to pricing pressure and rivalry from other weight loss players such as Eli Lilly and potential generic entrants.”
“Together, these factors will influence how durable Novo Nordisk’s obesity drug position looks relative to peers in the GLP 1 space.”
